ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.
|Journal||Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration|
|State||Accepted/In press - 1 Jan 2022|
- off-label treatment
ASJC Scopus subject areas
- Clinical Neurology